[Immunomodulation as innovative therapy for head and neck tumors : Current developments]

HNO. 2016 Jul;64(7):470-8. doi: 10.1007/s00106-016-0131-0.
[Article in German]

Abstract

Head and neck squamous cell carcinoma (HNSCC) is characterized by its intense immune suppression and its elaborate immune escape mechanisms. Due to the fact that survival rates remain low, the role of immunotherapy has become more important and the focus of current clinical studies has shifted toward antibody-based immune checkpoint modulation. Application of immunotherapy in curative settings or for prevention of recurrent disease would be desirable.

Keywords: Head and neck neoplasms; Immunotherapy; Monoclonal antibodies; Programmed cell death 1 receptor; Vaccination.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Cancer Vaccines / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / immunology*
  • Evidence-Based Medicine
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / immunology*
  • Humans
  • Immunologic Factors / immunology
  • Immunologic Factors / therapeutic use*
  • Immunotherapy / methods
  • Immunotherapy / trends*
  • Squamous Cell Carcinoma of Head and Neck
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Cancer Vaccines
  • Immunologic Factors